Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. NEJM evidence Koshino, A., Schechter, M., Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Rossing, P., Correa-Rotter, R., McMurray, J. J., Gorriz, J. L., Isidto, R., Kashihara, N., Langkilde, A. M., Wheeler, D. C., Heerspink, H. J. 2023; 2 (6): EVIDoa2300049

Abstract

DAPA and Anemia in Patients with CKDThis post hoc analysis of the DAPA-CKD (Dapagliflozin in Patients with Chronic Kidney Disease) trial assessed the impact of dapagliflozin treatment on the correction and prevention of anemia. Results over a 2.4-year median follow-up show that dapagliflozin is associated with increase in hematocrit, correction of anemia, and reduced risk of incident anemia in patients with CKD with or without type 2 diabetes.

View details for DOI 10.1056/EVIDoa2300049

View details for PubMedID 38320128